Adeona Pharma raises $3.5 million in new capital
Adeona Pharmaceuticals has increased its liquidity by $3.5 million after selling 1.6 million shares of common stock.The Ann Arbor-based company plans to use that new pool of money to further the development of its reaZin and Trimesta pharmaceutical programs. “It enables us to have the funding available for additional programs in the future,” says James Kou, CEO of Adeona Pharmaceuticals. “There are a lot of growth opportunities for us.”Adeona Pharmaceuticals specializes in drugs that address problems in the central nervous system, such as multiple sclerosis and Alzheimer’s. It commonly licenses these drugs at the clinical stage to large pharmaceutical companies.Trimesta, which is well into clinical trials, is being developed for the treatment of multiple sclerosis. So far the trial for the oral drug is 85 percent enrolled and is expected to fill completely later this year. Also in the midst of development is reaZin, a zinc-based medical food product candidate for Alzheimer’s.Source: James Kou, CEO of Adeona PharmaceuticalsWriter: Jon ZemkeRead more about Metro Detroit’s growing entrepreneurial ecosystem at SEMichiganStartup.com.
Adeona Pharmaceuticals has increased its liquidity by $3.5 million after selling 1.6 million shares of common stock.
The Ann Arbor-based company plans to use that new pool of money to further the development of its reaZin and Trimesta pharmaceutical programs. “It enables us to have the funding available for additional programs in the future,” says James Kou, CEO of Adeona Pharmaceuticals. “There are a lot of growth opportunities for us.”
Adeona Pharmaceuticals specializes in drugs that address problems in the central nervous system, such as multiple sclerosis and Alzheimer’s. It commonly licenses these drugs at the clinical stage to large pharmaceutical companies.
Trimesta, which is well into clinical trials, is being developed for the treatment of multiple sclerosis. So far the trial for the oral drug is 85 percent enrolled and is expected to fill completely later this year. Also in the midst of development is reaZin, a zinc-based medical food product candidate for Alzheimer’s.
Source: James Kou, CEO of Adeona Pharmaceuticals
Writer: Jon Zemke
Related Articles
On-Demand Coaching helps Ypsi’s government and small businesses build a winning team
A Michigan Municipal League program helps Ypsi and other municipalities connect small businesses and entrepreneurs with existing capital and technical assistance.
Ann Arbor DDA expands its boundaries for first time, enabling new projects on city’s North Side
The goal of the Ann Arbor Downtown Development Authority’s expansion is to strengthen connections between downtown, the Huron River, and Ann Arbor’s North Side.
Ann Arbor SPARK joins global network of innovation districts
Ann Arbor SPARK has joined The Global Institute on Innovation Districts Global Network, allowing it to collaborate with over 50 innovation districts in 14 countries.
